ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

Thomas Powles(St Bartholomew's Hospital), Sanjeev Mariathasan, Nicole N. Davarpanah(La Roche College), Daniel Castellano(Universidad Complutense de Madrid), Petros Grivas(Fred Hutch Cancer Center), Maha Hussain(University of Michigan), Siamak Daneshmand, Bernhard Zimmermann(Natera (United States)), David S. Shames(The University of Texas Southwestern Medical Center), Romain Banchereau, Kobe Yuen(La Roche College), Corey Carter(La Roche College), Zoe J. Assaf(La Roche College), Bernadett Szabados(Queen Mary University of London), Himanshu Sethi(Natera (United States)), Stéphane Oudard(Délégation Paris 5), Alexey Aleshin(Natera (United States)), Jürgen E. Gschwend(TUM Klinikum), Peter Albers(Düsseldorf University Hospital), Maurizio Perdicchio(Roche (Switzerland)), Hiroyuki Nishiyama(Kyoto University), Joaquim Bellmunt(Radboud University Nijmegen), Viraj Degaonkar(La Roche College), Xiaodong Shen, Carlos Bais(Eos Neuroscience (United States)), Shruti Sharma(Natera (United States)), Jingbin Zhang(Roche (Canada))
Nature
June 16, 2021
10.1038/s41586-021-03642-9
Cited by 603

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k